Evidence map›Paper›PMID 39677380›Full record

ReviewJournal of the Royal Society of New Zealand2025

The roles of immuno-modulator treatment and echocardiographic screening in rheumatic fever and rheumatic heart disease control: research from Aotearoa, New Zealand.

Nigel Wilson, Anneka Anderson, Michael G Baker, Julie Bennett, Adam Dennison, Reuben McGregor, Francis Middleton, Nicole J Moreland, Rachel Webb

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of the Royal Society of New Zealand, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nigel WilsonGreen Lane Paediatric and Congenital Cardiac Services, Starship Children's Hospital, Te Whatu Ora-Health New Zealand, Auckland, New Zealand.
Anneka AndersonTe Kupenga Hauora Māori, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand.
Michael G BakerDepartment of Public Health, University of Otago, Wellington, New Zealand.
Julie BennettDepartment of Public Health, University of Otago, Wellington, New Zealand.
Adam DennisonDepartment of Paediatrics, KidzFirst Children's Hospital, Te Whatu Ora-Health New Zealand, Counties Manukau, Auckland, New Zealand.
Reuben McGregorDepartment of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand.
Francis MiddletonDepartment of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand.
Nicole J MorelandDepartment of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand.
Rachel WebbDepartment of Paediatric Infectious Diseases, Starship Children's Hospital, Te Whatu Ora-Health New Zealand, Auckland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review summarises advances in research from Aotearoa, New Zealand (NZ) that have potential to reduce the inequitable distribution of acute rheumatic fever (ARF) and rheumatic heart disease (RHD). ARF incidence and RHD prevalence are unacceptably inequitable for Māori and Pacifica. Recent qualitative research has demonstrated mismatches between the lived experience of those with ARF/RHD and health service experience they encounter. NZ-led research has contributed knowledge to all stages of disease prevention (primordial, primary and secondary) and for tertiary management. Modifiable risk factors for ARF are racism across health sectors, household crowding, barriers to accessing primary health care, a high intake of sugar-sweetened beverages and preceding sore throat and skin infections. NZ research has evaluated the impact of a large-scale sore throat management programme and Streptococcal A vaccine development. This review highlights two programme domains of research by the authors that have the potential to reduce the burden of chronic RHD: firstly, effective immunomodulation of ARF to reduce the severity of carditis, with current clinical trials of hydroxychloroquine in NZ; secondly, the development of echocardiographic screening of previously undetected RHD. This now meets criteria for an effective screening test and has potential translation for disease control of RHD.

Indexed as

echocardiographic screeningImmuno-modulatorNew Zealandrheumatic feverrheumatic heart disease

Identifiers

PMID39677380
PMCPMC11639061

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.